cycloserine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 759 | 68-41-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antibiotic substance produced by Streptomyces garyphalus.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.75 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 100 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 65 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 163.58 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 29, 1964 | FDA | PURDUE GMP |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Electrocardiogram QT prolonged | 223.90 | 33.14 | 78 | 1732 | 59452 | 63427760 |
| Drug resistance | 125.64 | 33.14 | 40 | 1770 | 22893 | 63464319 |
| Neuropathy peripheral | 93.44 | 33.14 | 51 | 1759 | 113616 | 63373596 |
| Drug reaction with eosinophilia and systemic symptoms | 77.79 | 33.14 | 31 | 1779 | 33805 | 63453407 |
| Anaemia | 53.77 | 33.14 | 53 | 1757 | 293377 | 63193835 |
| Psychotic disorder | 53.69 | 33.14 | 22 | 1788 | 25690 | 63461522 |
| Hepatotoxicity | 52.17 | 33.14 | 24 | 1786 | 37017 | 63450195 |
| Optic neuropathy | 52.10 | 33.14 | 12 | 1798 | 2020 | 63485192 |
| Tuberculoma of central nervous system | 45.59 | 33.14 | 8 | 1802 | 339 | 63486873 |
| Optic neuritis | 43.19 | 33.14 | 14 | 1796 | 8421 | 63478791 |
| Off label use | 35.24 | 33.14 | 66 | 1744 | 674396 | 62812816 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Electrocardiogram QT prolonged | 355.61 | 32.24 | 125 | 2269 | 40827 | 34913710 |
| Hepatotoxicity | 153.56 | 32.24 | 57 | 2337 | 21428 | 34933109 |
| Neuropathy peripheral | 112.11 | 32.24 | 70 | 2324 | 83193 | 34871344 |
| Off label use | 73.41 | 32.24 | 114 | 2280 | 419410 | 34535127 |
| Intentional product use issue | 64.89 | 32.24 | 44 | 2350 | 59772 | 34894765 |
| Drug resistance | 62.50 | 32.24 | 32 | 2362 | 25895 | 34928642 |
| Optic neuritis | 59.67 | 32.24 | 18 | 2376 | 3556 | 34950981 |
| Anaemia | 42.69 | 32.24 | 65 | 2329 | 233270 | 34721267 |
| Optic neuropathy | 42.05 | 32.24 | 12 | 2382 | 1953 | 34952584 |
| Vomiting | 35.76 | 32.24 | 62 | 2332 | 247559 | 34706978 |
| Arrhythmia | 35.61 | 32.24 | 25 | 2369 | 35783 | 34918754 |
| Benign soft tissue neoplasm | 33.48 | 32.24 | 6 | 2388 | 116 | 34954421 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Electrocardiogram QT prolonged | 531.86 | 29.12 | 195 | 4142 | 90191 | 79649860 |
| Neuropathy peripheral | 213.41 | 29.12 | 118 | 4219 | 141187 | 79598864 |
| Hepatotoxicity | 195.26 | 29.12 | 81 | 4256 | 51271 | 79688780 |
| Drug resistance | 161.81 | 29.12 | 67 | 4270 | 42146 | 79697905 |
| Off label use | 101.67 | 29.12 | 178 | 4159 | 907037 | 78833014 |
| Optic neuritis | 100.60 | 29.12 | 32 | 4305 | 9488 | 79730563 |
| Optic neuropathy | 92.45 | 29.12 | 24 | 4313 | 3460 | 79736591 |
| Intentional product use issue | 90.36 | 29.12 | 71 | 4266 | 152041 | 79588010 |
| Anaemia | 86.25 | 29.12 | 113 | 4224 | 444902 | 79295149 |
| Psychotic disorder | 71.78 | 29.12 | 38 | 4299 | 41364 | 79698687 |
| Drug reaction with eosinophilia and systemic symptoms | 71.14 | 29.12 | 44 | 4293 | 64200 | 79675851 |
| Tuberculoma of central nervous system | 53.31 | 29.12 | 11 | 4326 | 576 | 79739475 |
| Vomiting | 52.50 | 29.12 | 113 | 4224 | 665715 | 79074336 |
| Aspartate aminotransferase increased | 44.90 | 29.12 | 46 | 4291 | 138595 | 79601456 |
| Toxic optic neuropathy | 40.79 | 29.12 | 10 | 4327 | 1143 | 79738908 |
| Tuberculosis | 38.32 | 29.12 | 18 | 4319 | 15180 | 79724871 |
| Arrhythmia | 37.15 | 29.12 | 29 | 4308 | 61243 | 79678808 |
| Pathogen resistance | 36.20 | 29.12 | 17 | 4320 | 14325 | 79725726 |
| Product use in unapproved indication | 35.60 | 29.12 | 55 | 4282 | 250304 | 79489747 |
| Pulmonary tuberculosis | 35.29 | 29.12 | 14 | 4323 | 7851 | 79732200 |
| Peripheral sensory neuropathy | 34.60 | 29.12 | 16 | 4321 | 13017 | 79727034 |
| Benign soft tissue neoplasm | 34.38 | 29.12 | 6 | 4331 | 126 | 79739925 |
| Tinnitus | 33.62 | 29.12 | 24 | 4313 | 44309 | 79695742 |
| Hypothyroidism | 32.20 | 29.12 | 25 | 4312 | 52367 | 79687684 |
| Hypokalaemia | 31.55 | 29.12 | 39 | 4298 | 144001 | 79596050 |
| Polyneuropathy | 30.46 | 29.12 | 18 | 4319 | 24133 | 79715918 |
| Deafness | 30.05 | 29.12 | 17 | 4320 | 21020 | 79719031 |
| Gastrointestinal disorder | 29.89 | 29.12 | 35 | 4302 | 122170 | 79617881 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J04AB01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Antibiotics |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000892 | Anti-Infective Agents, Urinary |
| MeSH PA | D000904 | Antibiotics, Antitubercular |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D000995 | Antitubercular Agents |
| MeSH PA | D009676 | Noxae |
| CHEBI has role | CHEBI:25212 | metabolites |
| CHEBI has role | CHEBI:33231 | antitubercular agents |
| CHEBI has role | CHEBI:35221 | antimetabolite |
| CHEBI has role | CHEBI:35441 | antiinfective agents |
| CHEBI has role | CHEBI:64571 | NMDAR agonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute tuberculosis | indication | 25629007 | |
| Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Bacterial urinary infection | indication | 312124009 | |
| Tuberculosis of meninges | off-label use | 58437007 | |
| Mycobacteriosis | off-label use | 88415009 | |
| Alcoholism | contraindication | 7200002 | |
| Depressive disorder | contraindication | 35489007 | |
| Sideroblastic anemia | contraindication | 41841004 | DOID:8955 |
| Megaloblastic anemia | contraindication | 53165003 | DOID:13382 |
| Acute nephropathy | contraindication | 58574008 | |
| Psychotic disorder | contraindication | 69322001 | |
| Severe anxiety (panic) | contraindication | 80583007 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Folic acid deficiency | contraindication | 190633005 | |
| Cobalamin deficiency | contraindication | 190634004 | |
| CNS Toxicity | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.38 | acidic |
| pKa2 | 6.74 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 3A | Ion channel | IC50 | 5.64 | WOMBAT-PK | |||||
| Glutamate receptor ionotropic, NMDA 2B | Ion channel | IC50 | 5.64 | WOMBAT-PK | |||||
| Glutamate receptor ionotropic, NMDA 2C | Ion channel | IC50 | 5.34 | WOMBAT-PK | |||||
| Glutamate receptor ionotropic, NMDA 2D | Ion channel | IC50 | 5.64 | WOMBAT-PK | |||||
| Glutamate receptor ionotropic, NMDA 1 | Ion channel | IC50 | 5.26 | WOMBAT-PK | |||||
| Glutamate receptor ionotropic, NMDA 3B | Ion channel | IC50 | 5.64 | WOMBAT-PK | |||||
| Glutamate receptor ionotropic, NMDA 2A | Ion channel | IC50 | 5.64 | WOMBAT-PK | |||||
| Cytochrome P450 3A4 | Enzyme | IC50 | 4.31 | WOMBAT-PK | |||||
| Alanine racemase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| D-alanine--D-alanine ligase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Alanine racemase | Enzyme | WOMBAT-PK | |||||||
| Glutamate receptor ionotropic, NMDA 1 | Ion channel | IC50 | 5.13 | CHEMBL | |||||
| Glutamate receptor ionotropic, NMDA 2C | Ion channel | EC50 | 4.74 | CHEMBL | |||||
| Glutamate NMDA receptor | Ion channel | IC50 | 5.64 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 95IK5KI84Z | UNII |
| 4019284 | VUID |
| N0000147483 | NUI |
| D00877 | KEGG_DRUG |
| 204225 | RXNORM |
| 4019284 | VANDF |
| C0010590 | UMLSCUI |
| CHEBI:23503 | CHEBI |
| 4AX | PDB_CHEM_ID |
| CHEMBL771 | ChEMBL_ID |
| 6234 | PUBCHEM_CID |
| DB00260 | DRUGBANK_ID |
| D003523 | MESH_DESCRIPTOR_UI |
| 577 | INN_ID |
| 1617 | MMSL |
| 4520 | MMSL |
| 51619 | MMSL |
| d01101 | MMSL |
| 002788 | NDDF |
| 387282000 | SNOMEDCT_US |
| 51334008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| SEROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1200 | CAPSULE | 250 mg | ORAL | ANDA | 19 sections |
| SEROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1200 | CAPSULE | 250 mg | ORAL | ANDA | 19 sections |
| CYCLOSERINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1201 | CAPSULE | 250 mg | ORAL | ANDA | 19 sections |
| CYCLOSERINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1201 | CAPSULE | 250 mg | ORAL | ANDA | 19 sections |
| Cycloserine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1202 | CAPSULE | 250 mg | ORAL | ANDA | 13 sections |
| Cycloserine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1202 | CAPSULE | 250 1 | ORAL | ANDA | 13 sections |
| Seromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1203 | CAPSULE | 250 mg | ORAL | ANDA | 21 sections |
| Seromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13845-1203 | CAPSULE | 250 mg | ORAL | ANDA | 21 sections |
| Cycloserine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-235 | CAPSULE | 250 mg | ORAL | ANDA | 13 sections |